Wednesday, January 27, 2021

Design Therapeutics Picks Up $125M For Small Molecules

San Diego-based Design Therapeutics, a biotech company which is developing small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, said it has raised $125M in its Series B funding round. The funding was led by Logos Cpaital, and also included Cormorant Asset Management, SR One, Quan Capital and WestRiver Group, plus funds and accounts managed by BlackRock, Janus Henderson Investors, RA Capital Management, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., Wellington Management, Avoro Capital Advisors, Vivo Capital, and others. The company said the funding will go to advance its pipeline. Arsani William, M.D., managing partner and chief investment officer of Logos Capital, and John Schmid, industry veteran and former chief financial officer of Auspex Pharmaceuticals, have both joined the company's board with the funding.